Ocaliva (obeticholic acid) - Important Safety Information from Intercept Pharma Ltd as approved by the HPRA (09.06.2022)

Notice type: 3rd Party Publications

Date: 10/06/2022




Problem Or Issue:

Important Safety Information from Intercept Pharma Ltd regarding Ocaliva (obeticholic acid): New contraindication for the treatment of primary biliary cholangitis (PBC)

in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation


Important Safety Information – Ocaliva (obeticholic acid)


« Back